The MCI Specialty Pharmacy, located at the main Mitchell Cancer Institute Office in Mobile, was launched in 2018.
By Carol McPhail
USA Health Mitchell Cancer Institute has achieved accreditation from the Utilization Review Accreditation Commission (URAC) for its specialty pharmacy. URAC is the independent leader in promoting healthcare quality through leadership, accreditation, measurement and innovation. By earning this accreditation, the MCI Specialty Pharmacy has demonstrated a comprehensive commitment to quality care, improved processes and better patient outcomes.
Opened in 2018, the MCI Specialty Pharmacy fills prescriptions for oral oncolytics, or chemotherapy taken by mouth, as well as supportive medications for cancer patients. The pharmacy is located at the main Mitchell Cancer Institute office in Mobile but also serves patients at MCI’s Fairhope and Springhill locations.
About 455 specialty pharmacies in the U.S. hold URAC accreditation.
“This accreditation demonstrates the quality of services that MCI provides for our patients and our physicians,” said Brittney Carden, Pharm D., pharmacy manager. “Increasingly, oncologists are prescribing oral chemotherapy, which requires special handling, real-time monitoring and more support than most other prescription drugs. The majority of chemotherapy drugs that are in the pipeline for future cancer treatments are oral, which validates the significance of having our own specialty pharmacy and being dually accredited by both URAC and the Accreditation Commission for Health Care.”
The MCI Specialty Pharmacy achieved accreditation from the Accreditation Commission for Health Care (ACHC) in 2018.